top of page


Find out which are the Development and Innovation Researches that Veritas works with its partners.

Âncora 1

Monoclonal Antibodies for Cancer

Monoclonal antibodies are designed for a particular antigen (target) on cancer cells and can initiate the immune response and destroy cancer cells without reaching normal cells. Such therapeutic targets are advancing into all areas of medicine.


Our focus is on discovering therapeutic targets for anti-metastatic therapies. We successfully completed the production and in vitro characterization of monoclonal antibodies (mAbs_VLS) with new immunotherapeutic potential for the control of metastatic cancer of epithelial origin. Our mAbs_VLS recognizes cancer cells and metastatic tissues and inhibits metastasis in vitro. We started the preclinical phase of development of this new biopharmaceutical for validation now in animal models.


Veritas opens up the possibility for the country to enter the cancer therapy market. Among the four product families that make up the oncology immunotherapeutic market, antibody mAbs represent the highest revenue percentage and have continued success in cancer therapy. There are few mAbs (among approved products and/or in advanced clinical stages) targeted at the treatment of advanced/metastatic stages of the disease. None of these mAbs have as their main mechanistic target the inhibition of the intercellular contact loss process by protecting the cleavage of our target protein.

Âncora 2

New Antibacterial Agents

Focus on the treatment of latent tuberculosis and diagnosis of tuberculosis. We built a Mycobacterium Tuberculosis Proteogenomic Database, identified a set of unpublished polypeptide sequences specific to the latent stage of the disease and have already started the development of an enzymatic assay aimed at identifying new drugs (small molecules) that inhibit the maintenance of the mycobacterium  in the latent phase.


The new molecular targets discovered by the Veritas team constitute mycobactericidal agents with a new mechanism of action for the treatment of tuberculosis. These targets, which have unique characteristics, are already in the process of registering patents by Veritas both for the development of a “screening” test for new drugs against tuberculosis and for its use as a new therapy against the disease.

Âncora 3

Platform and Strategy

Veritas leverages its unique and robust technology platform called the integrated-Proteomics Research System (i-PRS). This platform is made up of state-of-the-art proteomic technology, all integrated in a unique way in proprietary protocols that allow the rapid discovery of new compositions of biological matter with high biotechnological potential and commercial success. Our proven scientific competence and business strategy provide us with a clear path forward in the discovery, validation and commercialization of the products in our R&D pipeline, greatly reducing their development time and increasing the chances of clinical success.


Veritas products fit perfectly into the current trend of globalization of R&D activities in biotechnology that go beyond the simple past model of "outsourcing" of low added value services to CROs ("Contract Research Organizations") in lesser countries. developed in favor of a more collaborative model and true alliances for research.


Differential Proteomics and Cell Signaling:

Changes in protein expression and post-translational control are common regulatory mechanisms in all living cells. Post-translational modifications (PTM) for example, play an important role in several biological processes, including regulation of host-parasite interactions, oncogenesis and tumor progression, as well as regulation of stress responses in plants. Global and quantitative characterization of protein expression and post-translational modification patterns in multiple stages of  a tissue or organism (eg. Pathogenic VS. Non-pathogenic state; baseline VS. Stress), is a fundamental step in understanding the complexity and interconnectedness of biological regulatory networks.


Clinical Proteomics:

The application of robust and quantitative proteomic platforms to analyze clinical samples, combined with rigorous and standardized laboratory procedures in order to eliminate analytical variations, promises to accelerate the discovery of new targets and mechanisms for the development of therapies and diagnostics.


Biotechnological Remedies:

Biotechnological remedies are considered the future of the pharmaceutical industry. There are nearly 1000 biological medicines and vaccines in development. Chemical remedies will continue to exist, but the market for biotechs will be larger as we move towards personalized medicine. This clearly involves applying post-genomic technologies to discover the different characteristics between patient populations so that they can really benefit from personalized therapies. This new era of medicine will embrace the idea of providing the right treatment to the right patient at the right time.



Irish, J.M. et al. Mapping normal and cancer cell signalling: towards single-cell proteomics. Nature Reviews Cancer (2006) 6:146-155

Do it, V.M. et al. Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS ONE (2008) 3(6): e2425

Do it, V.M. et al. Mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Medicine (2008) 5(6): e123

Rikova, K. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell (2007) 131:1190-1203

Sheehan, K.M. et al. Signal pathway profiling of epithelial and stromal compartments of colonic carcinoma reveals epithelial-mesenchymal transition. Oncogene (2008) 27: 323-331

bottom of page